Video Series: Current Topics in the Treatment of Advanced PCa
Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.
Latest Prostate Cancer News
The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.
Findings support the use of a 5 grade-group system that more accurately reflects patient risk of adverse outcomes.
The odds of PSA screening were higher among blacks than non-Hispanic whites.
PSA level declined by an average of 0.68 ng/mL in the treatment group.
Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.
An early, integrated approach led to less deterioration of erectile function after surgery.
Researchers also suggests that statins may help counteract harmful effect of fatty foods.
Testosterone levels of 20 ng/dL or less were achieved and maintained by more than 90% of men with advanced prostate cancer.
Improved odds seen for patients with colon, prostate, or breast tumors, but research isn't definitive.
Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).
Researchers found that men who exercised the most had the best outcomes.
Metformin, a widely used oral anti-diabetic drug, enhanced the anti-prostate cancer activity of abiraterone and enzalutamide.
Fewer prostate cancer deaths may be yet another benefit of smoking cessation.
Prostate cancer patients with 2 or more comorbid diseases are more likely to have their cancer upgraded and up staged at RP.
Researchers find 23% increased risk compared to men who received other treatments.
Prostate Cancer Videos
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)